Hyperion DeFi Inc HYPD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.74
- Day Range
- $2.72–2.80
- 52-Week Range
- $2.49–15.45
- Bid/Ask
- $2.73 / $2.76
- Shares Outstanding
- 15.16M
- Market Cap
- $41.68M
- Volume/Avg
- 24,778 / 577,793
Key Statistics
- Price/Earnings (Normalized)
- 0.78
- Price/Sales
- 20.03
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Hyperion DeFi Inc is a USA-based company building a long-term strategic treasury of Hyperliquid's native token, HYPE. The Company is focused on providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest-growing and highest-revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its on-chain utility. It is working to provide its shareholders with simplified exposure to the Hyperliquid ecosystem, which is believed to be among the highest-revenue-generating blockchains in the world, according to information from various blockchain data tracking sources, including Artemis Analytics and DefiLlama.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.hyperiondefi.com
Valuation
|
Metric
|
HYPD
|
|---|---|
Price/Earnings (Normalized) | 0.78 |
Price/Book Value | 0.54 |
Price/Sales | 20.03 |
Price/Cash Flow | — |
Price/Earnings
HYPD
Financial Strength
|
Metric
|
HYPD
|
|---|---|
Quick Ratio | 1.73 |
Current Ratio | 1.97 |
Interest Coverage | −26.82 |
Quick Ratio
HYPD
Profitability
|
Metric
|
HYPD
|
|---|---|
Return on Assets (Normalized) | −3.44% |
Return on Equity (Normalized) | −4.63% |
Return on Invested Capital (Normalized) | −2.22% |
Return on Assets
HYPD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|VVkB<< | LOCK|P^rk | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|nmcPPNK | LOCK|qLp? | $71B | |||
| argenx SE ADR
ARGX
| LOCK|@Cn&n& | LOCK|Yj% | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|d^P@r>? | LOCK|>< | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#tgfSgC | LOCK|N%$@C | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$>xc>?Q | LOCK|#gNc | $26B | |||
| Moderna Inc
MRNA
| LOCK|N@s$#^ | LOCK|!! | $25B | |||
| Incyte Corp
INCY
| LOCK|x<^Y%@ | LOCK|jHq | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|cg%HZd | LOCK|XC | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?#<&p?& | LOCK|&^t | $16B |
United States